Gemcitabine (Gemzar)
The Predictive Value of ERCC1, RRM1, and Thymidylate Synthase in Advanced Malignant Pleural Mesothelioma Patients Treated with Platinum-Based Chemotherapy
Asian Pacific Journal of Cancer Prevention 2023 January 1 [Link] Nagwa Ismail Wahba, Ola Khorshid, Fatma Abo Elkasem, Abeer Bahnassy, Rabab Gaafer Abstract Background: A rare yet severe neoplasia called malignant pleural mesothelioma (MPM) typically manifests itself in advanced stages. Despite some improvements in the treatment of patients with MPM, this malignancy continues to have…
Read MoreUnusually Aggressive Presentation of Malignant Peritoneal Mesothelioma: Two Case Reports
Case Reports in Oncology 2022 November 8 [Link] Dominik Neff, Barbara-Christina Padberg Sgier, Hannah Dietze, Joachim Müller, Martin Früh Abstract Malignant peritoneal mesothelioma is a rare disease. Patients mainly present with abdominal distension, pain, nausea, and weight loss with or without an exposure history of asbestos. Diagnosis may be difficult from a clinical and histopathologic…
Read MoreMinimally important differences of EORTC QLQ-C30 scales in patients with lung cancer or malignant pleural mesothelioma – Interpretation guidance derived from two randomized EORTC trials
Lung Cancer 2022 March 29 [Link] Michael Koller, Jammbe Z Musoro, Krzysztof Tomaszewski, Corneel Coens, Madeleine T King, Mirjam A G Sprangers, Mogens Groenvold, Kim Cocks, Galina Velikova, Hans-Henning Flechtner, Andrew Bottomley Abstract Objectives: A minimally important difference (MID) is the smallest difference in quality of life (QoL) perceived as relevant by patients or clinicians.…
Read MoreEfficacy, Safety, and Cost-Minimization Analysis of Continuous Infusion of Low-Dose Gemcitabine Plus Cisplatin in Patients With Unresectable Malignant Pleural Mesothelioma
Frontiers in Oncology 2021 April 20 [Link] Oscar Arrieta, Wendy Muñoz-Montaño, Sae Muñiz-Hernández, Saul Campos, Rodrigo Catalán, Herman Soto-Molina, Silvia Guzmán Vázquez, Osvaldo Díaz-Álvarez, Victor Martínez-Pacheco, Jenny G Turcott, Maritza Ramos-Ramírez, Luis Cabrera-Miranda, Feliciano Barrón, Andrés F Cardona Abstract Background: Malignant pleural mesothelioma (MPM) is rare and aggressive neoplasia, with a poor prognosis; furthermore, the…
Read MoreSwitch-maintenance gemcitabine after first-line chemotherapy in patients with malignant mesothelioma (NVALT19): an investigator-initiated, randomised, open-label, phase 2 trial
The Lancet Respiratory Medicine 2021 January 27 [Link] Cornedine J de Gooijer, Vincent van der Noort, Jos A Stigt, Paul Baas, Bonne Biesma, Robin Cornelissen, Nico van Walree, Robbert C van Heemst, Magdolen Youssef-El Soud, Harry J M Groen, Agnes J Staal-van den Brekel, Wieneke A Buikhuisen, Gerben P Bootsma, Floris Dammeijer, Harm van Tinteren,…
Read MoreNew Imidazo[2,1- b][1,3,4]Thiadiazole Derivatives Inhibit FAK Phosphorylation and Potentiate the Antiproliferative Effects of Gemcitabine Through Modulation of the Human Equilibrative Nucleoside Transporter-1 in Peritoneal Mesothelioma
Anticancer Research 2020 September [Link] Giovanna Li Petri, Camilla Pecoraro, Ornella Randazzo, Silvia Zoppi, Stella Maria Cascioferro, Barbara Parrino, Daniela Carbone, Btissame El Hassouni, Andrea Cavazzoni, Nadia Zaffaroni, Girolamo Cirrincione, Patrizia Diana, Godefridus J Peters, Elisa Giovannetti Abstract Background/aim: A new class of imidazo[2,1-b][1,3,4]thiadiazole compounds have recently been evaluated as inhibitors of phosphorylation of focal…
Read MoreImpressive clinical response to anti-PD-1 therapy in epithelioid mesothelioma with high clonal PD-L1 expression and EML4-ALK rearrangement.
Lung Cancer 2020 February 14 [Link] Bronte G, Delmonte A, Burgio MA, Verlicchi A, Puccetti M, Bravaccini S, Cravero P, Tumedei MM, Diano D, Rossi G, Ulivi P, Martinelli G, Crinò L Abstract OBJECTIVES: Treatment options for malignant pleural mesothelioma (MPM) are limited but some studies on immune checkpoint inhibitors (ICIs) in MPM have reported…
Read MorePifithrin-μ induces necroptosis through oxidative mitochondrial damage but accompanies epithelial-mesenchymal transition-like phenomenon in malignant mesothelioma cells under lactic acidosis.
Archives of Pharmacal Research 2019 August 19 [Link] Abstract Heat shock protein 70 (HSP70), a chaperone protein associated with tumorigenesis and chemoresistance, has attracted significant attention as a potential therapeutic target for the development of anticancer drugs. Here, the effects of pifithrin-μ, an effective dual inhibitor of HSP70 and p53, on anticancer activities and epithelial-mesenchymal…
Read MoreBAP1 Status Determines the Sensitivity of Malignant Mesothelioma Cells to Gemcitabine Treatment.
International Journal of Molecular Sciences 2019 January 19 [Link] Guazzelli A, Meysami P, Bakker E, Demonacos C, Giordano A, Krstic-Demonacos M, Mutti L Abstract Malignant mesothelioma (MMe) is a cancer with poor prognosis and resistance to standard treatments. Recent reports have highlighted the role of the BRCA1 associated protein 1 gene (BAP1) in the development of MMe.…
Read MoreGemcitabine synergizes with immune checkpoint inhibitors and overcomes resistance in a preclinical model and mesothelioma patients.
Clinical Cancer Research 2018 August 28 [Link] Tallon de Lara P, Cecconi V, Hiltbrunner S, Yagita H, Friess M, Bode-Lesniewska B, Opitz I, Vrugt B, Weder W, Stolzmann P, Felley-Bosco E, Stahel RA, Tischler V, Britschgi C, Soldini D, van den Broek M, Curioni Fontecedro A Abstract
Read More